BiotechTube
Home/Pipeline/Technehexin

Technehexin

αvβ6 Integrin-positive Cancers

PreclinicalActive

Key Facts

Indication
αvβ6 Integrin-positive Cancers
Phase
Preclinical
Status
Active
Company
TRIMT

About TRIMT

TRIMT is a private, inventor-founded biotech company pioneering targeted radiopharmaceuticals for cancer theranostics. Its pipeline is centered on novel compounds targeting integrins like αvβ6 and αvβ8, as well as PD-L1, for both diagnostic imaging and radioligand therapy. The company leverages a strong scientific foundation, key academic collaborations, and an experienced leadership team to translate its discoveries from preclinical development into clinical trials.

View full company profile

Therapeutic Areas

Oncology

Other αvβ6 Integrin-positive Cancers Drugs

DrugCompanyPhase
TrivehexinTRIMTPreclinical
TherahexinTRIMTPreclinical
Undisclosed αvβ6 Integrin DxTRIMTDiscovery